Blood-Brain Barrier (BBB)

Monoclonal antibodies and some chemotherapeutic agents, exhibit poor central nervous system penetration largely due to their high molecular weight.¹

Compared to monoclonal antibodies, HER2 TKIs are characterised by different physico-chemical properties, in particular a considerably lower molecular weight, allowing them a more efficacious penetration through the blood-brain barrier.²

Job Code: UK/BC/2023/0022
Date of Preparation: November 2023